Prenuvo is a technology company.
Prenuvo offers comprehensive whole body MRI scans for preventative care, enabling early detection of health issues before they become serious.
Prenuvo has raised $190.0M across 2 funding rounds.
Prenuvo has raised $190.0M in total across 2 funding rounds.
# High-Level Overview
Prenuvo is a health technology company specializing in comprehensive whole-body MRI scans for early disease detection and proactive health monitoring.[1] The company offers radiation-free and contrast-free MRI screening that can detect over 500 conditions, including early-stage cancers and cardiovascular issues, generating approximately 1.3 billion data points across 33 organs in under 50 minutes.[4][5] Prenuvo serves health-conscious individuals, employers, and specialized programs for first responders, military members, and veterans, positioning itself at the intersection of preventive medicine and advanced imaging technology.[1]
Founded in 2018 and based in Los Angeles, California, Prenuvo has raised $191.8 million to date, including $120 million in Series B funding during 2024.[2][3] The company has surpassed 110,000 members and identified over 1.4 million personalized health insights across its member base, demonstrating significant traction in shifting consumer behavior toward proactive health management.[3] Its core mission is to flip the paradigm from reactive "sick-care" to proactive healthcare by combining optimized hardware, proprietary software, and increasingly AI-driven analysis with a patient-centric clinic experience across North America.[6]
# Core Differentiators
# Role in the Broader Tech Landscape
Prenuvo operates within a significant shift toward preventive healthcare and proactive disease detection, riding the wave of consumer demand for personalized health insights before symptoms emerge.[3] The company's timing is particularly advantageous as healthcare systems increasingly recognize the cost-effectiveness and human benefit of early detection over reactive treatment. Its large internal dataset of whole-body imaging—one of the largest in the industry—positions Prenuvo to drive constant innovation in AI-powered diagnostics and radiology analysis.[5]
The company influences the broader healthtech ecosystem by demonstrating a viable business model for preventive screening at scale. By combining hardware optimization, clinical expertise, and AI, Prenuvo establishes a template for how advanced imaging can be democratized beyond traditional hospital settings. Its focus on non-invasive, radiation-free screening also aligns with growing consumer preferences for safer diagnostic alternatives, potentially reshaping expectations around preventive care standards.
# Quick Take & Future Outlook
Prenuvo is positioned to lead the transformation in preventive healthcare by leveraging its unique integrated model—difficult to replicate due to its combination of proprietary imaging technology, clinical expertise, and AI capabilities.[3] The company's trajectory suggests expansion beyond individual consumers into employer wellness programs and specialized populations, with enhanced screening offerings rolling out across major metropolitan areas.
The convergence of three factors will likely shape Prenuvo's evolution: the growing adoption of AI for medical image analysis, increasing consumer willingness to invest in preventive health, and potential regulatory tailwinds as early detection demonstrates measurable health outcomes. As Prenuvo scales its member base and refines its AI models with an expanding dataset, the company could establish itself as the gold standard for whole-body preventive screening, fundamentally changing how individuals approach health monitoring before disease manifests.
Prenuvo has raised $190.0M in total across 2 funding rounds.
Prenuvo's investors include Camber Creek, Felicis Ventures, Forerunner Ventures, General Catalyst, Left Lane Capital, Moxxie Ventures, Openspace Ventures, super{set}, Y Combinator, Kevin Stumpf, Kulveer Taggar, Accel.
Prenuvo has raised $190.0M across 2 funding rounds. Most recently, it raised $120.0M Series B in February 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2025 | $120.0M Series B | Camber Creek, Felicis Ventures, Forerunner Ventures, General Catalyst, Left Lane Capital, Moxxie Ventures, Openspace Ventures, super{set}, Y Combinator, Kevin Stumpf, Kulveer Taggar | |
| Oct 1, 2022 | $70.0M Series A | Accel, AirAngels, Alumni Ventures, Asymmetric Capital Partners, Atlas Venture, Dreamers VC, Drive Capital, Felicis Ventures, Future Shape, General Catalyst, Innovation Endeavors, Moxxie Ventures, Openspace Ventures, SR One, Thirty Five Ventures, Y Combinator, Kevin Stumpf, Kulveer Taggar |